Key result
Two formulations of telmisartan were bioequivalent, with the 90% CI for AUC0–t, AUC0–∞, and Cmax meeting predefined acceptance criteria.
Why the study?
Telmisartan is a highly variable drug indicated for the treatment of hypertension, and this study aimed to compare the bioavailability of two 80 mg telmisartan tablets in healthy Indonesian subjects.
Are two formulations of 80 mg telmisartan bioequivalent in healthy subjects?
RCT (n=31)
Open-label
randomized
Are two formulations of 80 mg telmisartan bioequivalent in healthy subjects?
Two formulations of 80 mg telmisartan were found to be bioequivalent in healthy Indonesian subjects.
Answers are grounded in this paper and cite their sources.
May support generic substitution of telmisartan; leaves open outcome validation in broader populations.
Telmisartan is highly variable drug indicated for treatment of hypertension. This study aimed to compare the bioavailability of two 80 mg telmisartan tablets in healthy Indonesian subjects. A randomized, open-label, single-dose, three-sequence, three-way, reference-formulation-replicated crossover study was conducted under fasting period with two-week washout period. In this study, 31 Indonesian subjects were enrolled and 28 subjects were completed the study. Serial blood samples were collected up to 72 h following drug administration. Plasma concentrations of telmisartan were determined using high-performance liquid chromatography method with fluorescence detector. The pharmacokinetic parameters of AUC0–t, AUC0–∞, and Cmax were assessed for bioequivalence. Bioequivalence acceptance was based on predefined criteria of 90% confidence interval (CI) of 80.00–125.00% for AUC parameters and reference-scaled-average bioequivalence of 71.73–139.42% for Cmax. The 90% CI for AUC0–t, AUC0–∞, and Cmax was 96.11–107.25%, 93.06–104.36%, and 94.23–127.01%, respectively. These results indicated that the two formulations of telmisartan were bioequivalent.
No takes yet. Share an insight, caveat, or question.
Paramanindita et al. (2020) conducted an RCT in Healthy (n=31). Telmisartan vs. Reference formulation was evaluated on Bioequivalence assessed by AUC0–t, AUC0–∞, and Cmax. Two formulations of telmisartan were bioequivalent, with the 90% CI for AUC0–t, AUC0–∞, and Cmax meeting predefined acceptance criteria.
Synapse has enriched 10 related papers. Consider them for comparative context: